ANL 34.80 Increased By ▲ 0.83 (2.44%)
ASC 19.99 Increased By ▲ 0.43 (2.2%)
ASL 25.25 Decreased By ▼ -0.60 (-2.32%)
AVN 94.82 Increased By ▲ 4.61 (5.11%)
BOP 8.52 Increased By ▲ 0.11 (1.31%)
BYCO 12.67 Increased By ▲ 0.13 (1.04%)
DGKC 123.65 Decreased By ▼ -1.06 (-0.85%)
EPCL 47.40 Decreased By ▼ -0.25 (-0.52%)
FCCL 23.60 Decreased By ▼ -0.25 (-1.05%)
FFBL 26.95 Increased By ▲ 0.10 (0.37%)
FFL 18.44 Increased By ▲ 0.38 (2.1%)
HASCOL 10.95 Increased By ▲ 0.05 (0.46%)
HUBC 80.59 Increased By ▲ 0.08 (0.1%)
HUMNL 8.40 Decreased By ▼ -0.17 (-1.98%)
JSCL 22.80 Decreased By ▼ -0.06 (-0.26%)
KAPCO 43.44 Increased By ▲ 0.24 (0.56%)
KEL 4.18 Increased By ▲ 0.06 (1.46%)
LOTCHEM 15.90 Increased By ▲ 0.15 (0.95%)
MLCF 47.30 Decreased By ▼ -0.37 (-0.78%)
PAEL 35.05 Decreased By ▼ -0.05 (-0.14%)
PIBTL 11.68 Decreased By ▼ -0.18 (-1.52%)
POWER 9.90 Increased By ▲ 0.04 (0.41%)
PPL 90.00 Decreased By ▼ -0.06 (-0.07%)
PRL 25.68 Increased By ▲ 0.10 (0.39%)
PTC 12.17 Decreased By ▼ -0.22 (-1.78%)
SILK 1.94 Decreased By ▼ -0.14 (-6.73%)
SNGP 47.01 Decreased By ▼ -0.99 (-2.06%)
TRG 161.60 Decreased By ▼ -0.90 (-0.55%)
UNITY 42.75 Decreased By ▼ -1.46 (-3.3%)
WTL 3.85 Decreased By ▼ -0.01 (-0.26%)
BR100 5,230 Decreased By ▼ -11.3 (-0.22%)
BR30 27,235 Decreased By ▼ -112.49 (-0.41%)
KSE100 47,901 Decreased By ▼ -86.44 (-0.18%)
KSE30 19,259 Decreased By ▼ -65.68 (-0.34%)

Coronavirus
LOW Source: covid.gov.pk
Pakistan Deaths
22,073
3924hr
Pakistan Cases
950,768
93024hr
2.04% positivity
Sindh
333,194
Punjab
345,251
Balochistan
26,776
Islamabad
82,431
KPK
137,247

Hilton Pharma, a top research based pharmaceutical company of Pakistan and manufacturer of quality medicines is supporting National Institute of Blood Disease (NIBD) in conducting a clinical trial where blood plasma collected from recovered COVID-19 patients is transfused to moderate and severely ill patients of COVID-19.

The initial results of 14 patients released by Dr. Tahir Shamsi of NIBD, shows a promising response of up to more than 80% recovery rate; Patients were administered with plasma therapy at the stage of moderate to severe disease and their condition was eventually prevented from further deterioration or progressing to a stage requiring ventilator. These initial outcomes also conform to the results of similar ongoing trials across the world. The trial will continue to have enough local patient data to help medical community in developing guidelines about the use of plasma therapy in COVID-19 patients.

"It is quite heartening to see these initial trial results as they will eventually create enough evidence for doctors and scientists to overcome the eminent threat looming over the world, at large," said Dr. Tahir Shamsi. "We are extremely hopeful that plasma therapy may serve as a great breakthrough. This is an orthodox way of treatment used in other pandemics in the absence of a proven treatment."

Dr. Tahir Shamsi started this initiative in Pakistan and to support his efforts Hilton Pharma provided a research grant and partnered technically with the clinical trial team. The trial is being conducted in various hospitals of Sindh, Punjab, and KPK. The plasma of a recovered patient contains antibodies which when injected in an active patient of COVID-19, helps in fighting the virus and provides the patient with sufficient time to develop his [or her] own immunity to combat the virus.

This trial of national importance is approved by all Provincial Governments, Bioethics Committees, Ministry of National Health Services Regulations & Coordination, and Pharmacy Services of DRAP. The trial is also registered globally with WHO and FDA trial site.-PR

Copyright Business Recorder, 2020